Atyr Pharma Inc (LIFE)

$1.9

Market is closed - opens 7 PM, 19 Jul 2024

Highlights

Market Capitalization
131.1M
Book Value
$1.24
Earnings Per Share (EPS)
-0.88
PEG Ratio
0.0
Wall Street Target Price
24.6
Profit Margin
0.0%
Operating Margin TTM
-7079.15%
Return On Assets TTM
-29.37%
Return On Equity TTM
-55.61%
Revenue TTM
588.0K
Revenue Per Share TTM
0.01
Quarterly Revenue Growth YOY
-100.0%
Gross Profit TTM
-32.4M
EBITDA
-58.1M
Diluted Eps TTM
-0.88
Quarterly Earnings Growth YOY
0.0
EPS Estimate Current Year
-0.93
EPS Estimate Next Year
-0.75
EPS Estimate Current Quarter
-0.24
EPS Estimate Next Quarter
-0.24

Analyst Recommendation

Buy
    90%Buy
    9%Hold
    0
    0%Sell
Based on 11 Wall street analysts offering stock ratings for Atyr Pharma Inc(by analysts ranked 0 to 5 stars)
Based on 11 analyst
  • Current
  • 1M Ago
  • 3M Ago
Buy
10
10
10
Hold
1
1
1
Sell
00
00
00

Analyst Forecast

What analysts predicted

Upside of 1194.74%

Current $1.90
Target $24.60

Technicals Summary

Sell

Neutral

Buy

Atyr Pharma Inc is currently in a favorable trading position ( BUY ) according to technical analysis indicators.

Peers

Company Name1 Month6 Month1 Year3 Years5 Years
Company NameP/E RatioP/B RatioPEG RatioEPSROEROADiv YieldBVPS
Company NameAnalyst ViewMarket Cap5 Years Return %PE RatioProfit Margin

Institutional Holdings

  • Federated Hermes Inc

    14.74%
  • FMR Inc

    12.73%
  • Logos Global Management LP

    4.49%
  • Vanguard Group Inc

    3.84%
  • Tikvah Management LLC

    3.57%
  • Woodline Partners LP

    2.44%

Company Information

atyr pharma (nasdaq: life) is engaged in the discovery and clinical development of innovative medicines for patients suffering from severe rare diseases using its knowledge of physiocrine biology, a newly discovered set of physiological modulators. the company's lead candidate, resolaris™, is a first-in-class intravenous protein therapeutic for the treatment of rare myopathies with an immune component. resolaris is currently in a phase 1b/2 clinical trial in adult patients with facioscapulohumeral muscular dystrophy (fshd); a phase 1b/2 trial in adult patients with limb girdle muscular dystrophy (lgmd) 2b or fshd; and a phase 1b/2 trial in patients with an early onset form of fshd. to protect this pipeline, atyr built an intellectual property estate comprising 70 issued or allowed patents and over 240 pending patent applications that are solely owned or exclusively licensed by atyr. atyr's key programs are currently focused on severe, rare diseases characterized by immune dysregulation

Organization
Atyr Pharma Inc
Employees
56
CEO
Dr. Sanjay S. Shukla M.D., M.S.
Industry
Health Technology

FAQs